

CHI ACADEMY fa

CONTINUED HEALTHCARE LEARNING

INTRODUCTION

- Interactive "choose-your-path" digital algorithm
- Branching logic to facilitate real-time application of new guidelines and treatment options for advanced melanoma
- Content expands and contracts according to selected clinical and patient characteristics
- Anchored tool for HCPs ongoing use to validate real-world decision-making

TARGET AUDIENCE

Oncologists, dermatologists, and other members of the clinical team who treat patients with melanoma

OBJECTIVES & OUTCOMES METHODOLOGY

Practice Gap	Learning Objective	Expected Outcome	Measures
Clinicians have suboptimal knowledge of the MOA of LAG-3 inhibitors and the implications for addressing unmet needs in the treatment of advanced melanoma.	Review rationale for use of anti-LAG-3 inhibitors for the treatment of advanced melanoma	Clinicians understand the MOA of LAG-3 inhibitors and their potential synergistic effect in combination with PD-1 inhibitors to improve treatment outcomes in patients with advanced melanoma	Knowledge acquisition of anti- LAG-3 MOA Familiarity with MOA of anti- LAG-3 immunotherapies
Oncologists and other clinicians may not be up to date on the latest clinical trial evidence supporting the use of anti-LAG-3 immunotherapies in melanoma and therefore lack competency in interpreting and applying this evidence towards clinical decision- making.	Apply best practices in appropriate selection of anti-LAG-3 immunotherapy combinations for advanced melanoma, taking into account clinical trial findings, guidelines, and patient characteristics	Clinicians apply updated treatment guidelines and recent clinical trial evidence for LAG-3 inhibitors in clinical practice for patients with advanced melanoma who are appropriate for LAG-3/PD-1 combination therapy	Clinical competency with treatment selection and treatment sequencing Confidence with treatment selection and treatment sequencing Familiarity with clinical trial efficacy and safety profiles of combination immunotherapy
Oncologists and other clinicians treating advanced melanoma need education that addresses differentiating, mitigating, monitoring, and managing immune-related adverse events (irAEs) to improve patient outcomes.	Enhance the role of the multidisciplinary care team in the monitoring, management, and mitigation of adverse events associated with anti-LAG-3 combination therapy	Clinicians manage irAEs in a multidisciplinary manner to optimize ongoing treatment and monitoring of patients with advanced melanoma treated with immune checkpoint inhibitor therapies, including LAG-3/PD-1 combination therapy	Knowledge acquisition of management of lirAEs Confidence with the management of irAEs

ACTIVITY DETAILS

FACULTY



Hussein Tawbi, MD, PhD (Chair) Professor, Department of Melanoma Medical Oncology **Division of Cancer Medicine** The University of Texas MD Anderson Cancer Center Houston, TX



April Salama, MD (Faculty) Associate Professor of Medicine Medical Oncology Director of the Melanoma Program Duke Cancer Institute Duke University School of Medicine Durham, NC

Pathways to **Developing Personalized** Treatment Regimens for Patients with Advanced Melanoma Learn More 500 B


"While we are generally prone to use regimens that demonstrate highest efficacy, we need to balance these choices with incidence of toxicity... we also take into account patient performance status, patient preferences, patient comorbidities, and other social and environmental factors that may be relevant to patient decision-making so we can make the treatment

decisions with them. This algorithm can support that effort." – Hussein Tawbi, MD, PhD

DEMOGRAPHICS Specialty Oncology Dermatology Hospitalist Surgery General Practice Other Other HCPs include allergy/immunology, cardiology, emergency medicine, ophthalmology, pain management, pathology, psychiatry, radiology, neurology **ENGAGEMENT** 326 Repeat Learners 3.11 average visits among repeat learners 3x higher repeat engagement among oncologists **Total Slide Views** (n=15,086) 22% Evolution of Systemic Therapy Pathways for Treatment Selection Maintaining Patients on ICI 26% Therapy **RESULTS** Knowledge acquisition: Mechanism o anti-LAG-3 MOA in Action combination with other immunotherapies Clinical competence: treatment selection for Treatment advanced melanoma, 1 Selection metastatic disease site at liver, and without an activating BRAF mutation Knowledge acquisition: Treatment evidence from Sequencing DREAMseq clinical trial Knowledge acquisition: educating patients on anagement of irAEs toxicity profiles, including symptoms and timing

Pathways to Developing Personalized Treatment **Regimens for Patients With Advanced Melanoma**

Vanessa Senatore, Jonathan Sokolowski, PhD, and Katlyn Cooper Academy for Continued Healthcare Learning (ACHL)



Oncology

(n=273)

Dermatology

(n=112)


Other HCPs

(n=458)

PROGRAM IMPACT

A Cohen's d effect size of 0.62 indicates that participating clinicians are now 39% more knowledgeable of the content assessed than prior to participating in this education. (Cohen's d [1986]: 0.2=small; 0.5=medium, 0.8=large effect.)

Confidence and Familiarity Gains (n=843)



Improved confidence with initial treatment selection for patients with unresectable metastatic melanoma Improved confidence with treatment sequencing for patients with unresectable/metastatic melanoma and an activating **BRAF** mutation Improved confidence with managing irAEs related to


Increased familiarity with the MOA of anti-LAG-3 immunotherapies

immune checkpoint inhibitors


Increased familiarity with clinical trial efficacy of combination therapies incorporating an anti-LAG-3 agent

Increased familiarity with safety profile of combination immunotherapies incorporating an anti-LAG-3 agent

Intended Practice Changes (n=552)




Average Patients Impacted per Month by Changes in Practice (n=843) (Self-reported by Frequency of Actions Taken Pre- and Post-Activity)



LEARNER-REPORTED TAKEWAYS

• "Earlier use of LAG-3 inhibitors in combination with ICI"

- "Better efficacy with PD-1 and LAG-3 than single agent PD-1"
- "Synergistic effect mechanisms of anti LAG-3 antibodies"
- "Patient characteristics are the most important thing to consider with regards to balancing treatment efficacy with toxicity concerns."
- the disease."
- "I learned that anti-LAG-3 antibodies can promote the release of proinflammatory cytokines. I feel that this may be the reason we've seen so many patients have infusion reactions to nivo + rela vs just nivo alone."



Presented September 2024, at the Alliance Industry Summit; Philadelphia, PA

